## PREDICTORS FOR SARS-COV-2 IMMUNITY

#### 1 Predictors for Reactogenicity and Humoral Immunity to SARS-CoV-2 Following Infection and mRNA

#### 2 Vaccination: A Regularized Mixed-Effects Modelling Approach

- Erin C. Williams<sup>1,3</sup>, Alexander Kizhner<sup>2</sup>, Valerie S. Stark<sup>1,4</sup>, Aria Nawab<sup>1</sup>, Daniel D. Muniz<sup>1</sup>, Felipe Echeverri 3
- Tribin<sup>3</sup>, Juan Manuel Carreño<sup>6</sup>, Dominika Bielak<sup>6</sup>, Gagandeep Singh<sup>6</sup>, Michael E. Hoffer<sup>1,5</sup>, Florian 4
- Krammer<sup>6,7</sup>, Suresh Pallikkuth<sup>2</sup>, and Savita Pahwa<sup>2</sup> 5
- 6 <sup>1</sup>Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, 33136 USA
- 7 <sup>2</sup> Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida,
- 8 33146, USA
- 9 <sup>3</sup>Department of Biomedical Engineering, University of Miami, Miami, Florida, 33136, USA
- 10 <sup>4</sup> University of Miami Miller School of Medicine, Miami, Florida, 33136, USA
- <sup>5</sup> Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, Florida, 33136, USA 11
- <sup>6</sup> Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, 10029, USA 12
- <sup>7</sup> Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New 13
- 14 York, New York, 10029, USA
- 15
- 16 **Corresponding author**: Savita Pahwa, M.D. at the Department of Microbiology and Immunology
- 17 (Pediatrics and Medicine), University of Miami Miller School of Medicine, 1580 NW 10th Avenue; BCRI
- 712, Miami, FL 33136, USA. 18
- E-mail: spahwa@med.miami.edu 19
- 20 Phone: 305-243-7732
- 21 Fax: 305-243-7211
- 22
- 23 Word Count: 3499
- 24 Abstract Word Count: 191
- 25

### 26

## 27 Background

- 28 The influence of pre-existing humoral immunity, inter-individual demographic factors, and vaccine-
- associated reactogenicity on immunogenicity following COVID vaccination remains poorly understood.
- 30 Methods
- 31 Ten-fold cross-validated least absolute shrinkage and selection operator (LASSO) and linear mixed
- 32 effects models were used to evaluate symptoms experienced during natural infection and following
- 33 SARS-CoV-2 mRNA vaccination along with demographics as predictors for antibody (AB) responses in
- 34 COVID+ participants in a longitudinal cohort study.

## 35 Results

- 36 In previously infected individuals, AB were more durable and robust following vaccination when
- 37 compared to natural infection alone. Higher AB were associated with experiencing dyspnea during
- 38 natural infection, as was the total number of symptoms reported during the COVID-19 disease course.
- Both local and systemic symptoms following 1<sup>st</sup> and 2<sup>nd</sup> dose of SARS-CoV-2 mRNA vaccines were
- 40 predictive of higher AB after vaccination, as were the demographic factors of age and Hispanic ethnicity.
- 41 Lastly, there was a significant temporal relationship between AB and days since infection or vaccination.

## 42 Conclusion

- 43 Vaccination in COVID+ individuals ensures a more robust immune response. Experiencing systemic and
- 44 local symptoms post-vaccine is suggestive of higher AB, which may confer greater protection. Age and
- 45 Hispanic ethnicity are predictive of higher AB.

46

47 Keywords: COVID-19, protective antibodies, vaccine reactogenicity

# 48 Introduction

49	The heterogeneous presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
50	associated with inter-individual factors [1, 2], including age, biological sex, comorbidities, individual
51	susceptibility to the virus, exposure load, viral shedding, pre-existing binding or neutralizing antibodies
52	[3, 4], and pre-existing cross-reactive T cells [5-7]. Variability in these factors and their distinct
53	contributions to the individual immune response has made it difficult to generalize the clinical disease
54	course of SARS-CoV-2-infected individuals [1, 8]. Immunoassays have been used extensively throughout
55	the COVID-19 pandemic [9]. Their primary utility lies in characterizing the immune response following
56	vaccination, assessing viability for convalescent plasma donation, and acting as a population surveillance
57	tool [10, 11] though the most pressing work remains developing correlates for protection. Neutralizing
58	and binding titers remain well supported as protective markers [3, 12] regardless of natural infection or
59	vaccination, including a recent study [13] which associated increased binding and neutralizing antibodies
60	with an inverse risk for SARS-CoV-2 infection following mRNA-1273 (Moderna) vaccination.
61	
62	Previous studies have evaluated change in peak post-vaccination antibody titers as a function of time
63	[14] and the relationship between quantitative antibodies and disease severity [15]. Additionally, there
64	is evidence suggesting that antibody titers in vaccinated, previously coronavirus disease 2019 (COVID-
65	19) positive individuals [16-19] can predict the degree of individual immune protection [20]. The aim of
66	this paper is to investigate relationships between sociodemographic factors, reactogenicity, and
67	immunogenicity following SARS-CoV-2 mRNA vaccination in previously SARS-CoV-2 infected participants.
68	This analysis addresses a gap in the current COVID-19 literature that may help elucidate how pre-
69	existing immunity and vaccine reactogenicity are associated with post-vaccination antibody titers (i.e.,
70	humoral immunogenicity).

71

72	While a reactogenic response (i.e., short-term symptoms such as injection-site pain, fever, myalgia, etc.)
73	is expected following vaccination [19], there is no current evidence to support a relationship between
74	reactogenicity and immunogenicity for COVID-19 vaccines. We also address a major clinical question
75	regarding how severity of the COVID-19 disease course influences immunogenicity following SARS-CoV-2
76	vaccination. Conclusions drawn from this study may contribute to a more personalized public health
77	approach to future COVID-19 vaccine strategies, which could account for an individual's demographics
78	(e.g., age, gender, or race) or existing immunity prior to vaccination receipt [21].
79	
80	Methods
81	Study Design and Participants
82	We included a subset of individuals who are enrolled in our IRB-approved (#20201026), longitudinal,
83	prospective SARS-CoV-2 immunity study. Following the written informed consent process, participants
84	answered questions detailing their demographics, lifestyle habits, past medical history (including COVID-

19), and COVID-19 infection symptoms. Blood samples were collected for serum and peripheral blood

86 mononuclear cell (PBMC) processing. Plasma was stored at -80°C and PBMCs were cryopreserved in

87 liquid N2 [22]. All participants agreed to sample banking for future research use.

88

Participants who were enrolled in the study between October 2020 – June 2021 and had a history of
COVID-19 were included in this analysis. mRNA vaccines (Pfizer (BNT162b2) and Moderna (mRNA1273)) were the only options available [9] during the enrollment period and therefore most participants
received mRNA vaccines. Individuals who only received one dose of an mRNA vaccine or received the
Johnson & Johnson vaccine were excluded. Additionally, participants who were administered their
second dose of an mRNA vaccine >7 days after or <4 days before the recommended [23] number of days</li>
after the first dose (21 days for Pfizer; 28 days for Moderna) were excluded in order to account for the

96	temporal, transient nature of post-vaccine reactogenicity and the subsequent immune response in order
97	to best reflect the general population. Individuals with SARS-CoV-2 re-infection or breakthrough
98	infection were also excluded. All samples provided during the baseline visit and thereafter were
99	included in this analysis.
100	
101	Participants who received vaccines were instructed to return for two additional visits, where they
102	answered binary "Yes/No" questions in a survey about their symptoms following vaccination. Symptoms

- 103 were rated on a Likert scale, where a "0" indicated no symptoms and a "10" indicated the highest
- symptom severity. They also provided blood samples, which were processed for PBMCs and plasma as
- described above. Fourteen days after participants received Dose 2, we classified them as "fully

106 vaccinated".

107

108 Enzyme-Linked Immunosorbent Assay (ELISA)

109 SARS-CoV-2 ELISAs were performed using a well-described assay developed by the Icahn School of 110 Medicine at Mount Sinai [10, 11]. Briefly, 96-well plates were coated at 4 °C with SARS-CoV-2 spike 111 protein (2 µg/ml) solution and incubated overnight. Plates were blocked with 3% non-fat milk prepared 112 in PBS with 0.1% Tween 20 (PBST) and incubated at room temperature for 1h. After blocking, serial 113 dilutions of heat inactivated serum samples were added to the plates and incubated for 2h at room 114 temperature. Plates were washed three times with 0.1% PBST followed by addition of a 1:3,000 dilution 115 of goat anti-human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (50µl) well and 116 incubated 1h. Plates were washed, 100 μl SIGMAFAST OPD (o-phenylenediamine dihydrochloride;) 117 solution was added to each well for 10 min and then the reaction was stopped by the addition of  $50\mu$ l 118 per well of 3M hydrochloric acid. The optical density at 490nm (OD490) was measured using a Synergy 4 119 (BioTek) plate reader. The background value was set at an OD490 of 0.15 then discrete titers were

120	reported in values of 1:	100, 1:200, 1:400	, 1:800, 1:1600,	1:3200, 1:6400,	1:12800, 1:25600,	1:51200,

121 1:102400, and 1:204800. The limit of detection was set at 1:100.

122

123 Statistical Analysis

124 SARS-CoV-2 antibody titers were log2-transformed before all statistical analyses. We utilized a 125 generalized additive model to model the bi-phasic change in antibodies over time, including the rate of 126 antibody decay following natural infection (after last positive SARS-CoV-2 test [LPT] result) and full 127 vaccination ( $\geq$ 14 days after the second mRNA vaccine dose) [24] by modelling antibody titers with the 128 smooth function number of days elapsed using a cubic regression with 3 knots and the fixed effect of 129 vaccination status (after natural infection/pre-vaccination and after full vaccination). We replicated the 130 above as a linear mixed-effects model (LMM), where we incorporated the same fixed effects but 131 included participants as a random-intercepts effect to control for individual differences. The rates of log-132 transformed antibody titer decay along with the limit of detection of our assay were used to estimate 133 the number of days that the antibodies remain detectable after both natural infection and full 134 vaccination. 135 136 Ten-fold cross-validated least absolute shrinkage and selection operator (LASSO) models were employed 137 as a feature-selection and regularization technique. The LASSO models were tuned to select the simplest 138 model within one standard error of the lowest value root-mean-square error accuracy metric that 139 included at least two predictors (Supplementary Table 1). Four LASSO models with identical 140 demographic variables were constructed while controlling for time or days since LPT, 1st dose, or 2nd 141 dose, respectively, including: 1) the effect of infection symptoms on the antibody response post-142 infection, 2) the effect of infection symptoms on the antibody response post full vaccination, 3) the 143 effect of dose 1 vaccine symptoms on the antibody response post full vaccination, and 4) the effect of

144	dose 2 vaccine symptoms on the antibody response post full vaccination. The selected predictors from
145	each of the best-fitting cross-validated LASSO models were then included as fixed effects in follow-up
146	LMMs with by-participant random intercepts, allowing us to control for individual differences. For
147	significant categorical fixed effects from the LMMs, we conducted post-hoc Tukey tests to confirm
148	directionality and to correct for multiple comparisons.
149	
150	Additional linear regressions were used to investigate effects of each symptom following infection, 1 <sup>st</sup>
151	dose of vaccination, and 2 <sup>nd</sup> dose of vaccination and explore possible relationships between
152	demographics factors on peak antibody titer levels following full vaccination. Analyses were performed
153	using R statistical software Version 4.1.1 [24]. Generalized additive modeling, cross-validation, LASSO
154	modelling, LMM, and post-hoc Tukey tests were conducted with the R packages mgcv [25], caret [26],
155	glmnet [27], nlme [28], and glht [29], respectively, while the linear modelling, Mann-Whitney U tests,
156	and Kruskal-Wallace tests were performed using the R package stats [24]. Plots were produced using the
157	ggplot2 [30].
158	
159	Results
160	Characteristics of the Study Population
161	Demographic characteristics are detailed in Table 1. Thirty-three participants were included in our post
162	infection cohort. The median number of days since LPT to entry into the study was 101 days. For the

163 post dose 1 and post dose 2 analysis, we included 49 and 48 participants, respectively.

- 165 Symptoms Reported Following Infection and Vaccination
- 166 The highest reported symptom during the vaccine-naïve COVID-19 course was fatigue (63%) (Table 2).
- 167 Other highly reported symptoms included anosmia (55%), congestion (53%), and myalgias/muscle aches

168	(57%). Following dose 1, the most common symptoms were injection site pain (51%), headache (29%),
169	and fatigue (29%). Similarly, the most common symptoms reported following the second mRNA
170	vaccination (dose 2) were injection site pain (53%), fatigue (39%), and myalgias (29%) (Table 2).
171	
172	In Previously Infected Individuals, Antibody Titers Are More Robust Following Full-Vaccination as
173	Compared to Post Natural Infection
174	We found that there was a more robust antibody response immediately following full vaccination
175	(Figure 1C) when compared to the antibody response following natural infection (estimate = 4.117, $t$ =
176	12.950, $p = < 0.001$ ) (Figure 1B), where peak log <sub>2</sub> antibody titers where greater in the vaccination with
177	prior infection (14.517) than in natural infection (9.217). This is illustrated in Figure 1A, where natural
178	infection and post-full vaccination titers were included in a bi-phasic model to show longitudinal
179	antibody responses. Infected individuals had a slower rate of antibody titer decay (-0.010 vs -0.015 log
180	per day), though this effect was small (estimate = $-0.005$ , $t = 2.351$ , $p = 0.020$ ). Our linear model also
181	predicted that antibody titers remain detectable for a longer period of time after full vaccination (535
182	days) compared to natural infection alone (404 days), using the respective rates of antibody decay and
183	the limit of detection for our assay. Additional LMMs confirmed our findings that antibody titer declined
184	faster following full vaccination than in natural infection (estimate = $-0.006$ , F =11.238, p < 0.001). Of
185	note, the combination of natural infection followed by vaccination, or so-called "hybrid immunity",
186	elicits a more durable antibody response than natural infection alone (estimate = 4.138, $F$ = 794.623, $p$ <
187	0.0001), as $\log_2$ antibody titers were predicted to remain detectable for a longer period of time following
188	vaccination (550 days) than natural infection (464 days).
189	
190	Days Elapsed and Symptoms Reported During Infection Influence Antibody Titers

191 As shown in Table 3, difficulty breathing during infection (estimate = 1.590, F = 5.684, p = 0.024) and 192 days elapsed since LPT (estimate = -0.006, F = 9.912, p = .004) were significant main effects in predicting 193 antibody titers following natural infection. Post-hoc testing confirmed that antibody titers were elevated 194 in individuals who experienced difficulty breathing (z = 2.612; p = 0.009). 195 196 When modeling demographics and symptoms at infection to predict the antibody response after full 197 vaccination, we found that days elapsed since full vaccination (estimate = -0.014; F = 258.176; p < 0.0001), age (estimate = 0.018; F = 6.000; p = 0.019), and ethnicity (Hispanic) (estimate = 0.456; F = 198 199 5.265; p = 0.018) were significant main effects, though no categorical variables were significant after 200 post-hoc testing. 201 202 Symptoms Following Vaccination Are Predictive of Higher Antibody Titers After Full Vaccination 203 Local and systemic symptoms following 1<sup>st</sup> dose of SARS-CoV-2 mRNA vaccines were predictive of higher 204 antibody titers after full vaccination. As seen in Table 3, the results of the LMM show that days elapsed 205 since full vaccination (estimate = -0.014, F = 262.855, p < 0.0001), chills (estimate = 0.541; F = 4.915; p = 206 0.032), injection site redness (estimate = 1.243; F = 4.330; p = 0.044), age (estimate = 0.021; F = 6.960; p 207 = 0.012), and ethnicity (estimate = 0.562, F = 4.583, p = 0.038) were significant. Following post-hoc 208 Tukey testing on the significant categorical main effects, we found that injection site redness (z = 2.081, 209 p = 0.038) and ethnicity (Hispanic) (z = 2.382, p = 0.017) were significant, while the main effect of chills 210 was not. 211 We also examined demographics and symptoms reported during the 2<sup>nd</sup> dose of SARS-CoV-2 mRNA 212 213 vaccination and their effect on the antibody response after full vaccination. Days since full vaccination

(estimate = -0.014; F = 259.745; p < 0.0001), age (estimate = 0.023; F = 7.652; p = 0.009), identifying as

214

215	Hispanic (estimate = 0.609; $F$ = 6.683; $p$ = 0.013), fever (estimate = 0.839; $F$ = 11.154, $p$ = 0.002), and
216	influenza vaccination (estimate = -0.475; $F = 4.405$ ; $p = 0.042$ ) were observed to be significant. Fever
217	and ethnicity (Hispanic) were found to be statistically significant ( $z = 3.016$ , $p = 0.003$ ; $z = 2.735$ , $p =$
218	0.006, respectively) following post-hoc testing, though influenza vaccination was not.
219	
220	The Number of Symptoms During Infection Result in Higher Peak Antibody Titers Post Full-Vaccination
221	As shown in Figure 2, the number of symptoms reported during infection significantly predicted peak
222	antibody titers after full vaccination (estimate = 0.10, $t$ = 2.10, Pearson's $r$ = 0.296; $p$ = .041). Additional
223	linear models were conducted for the number of symptoms reported as a function of demographics,
224	where we found that the number of symptoms self-reported during infection was significantly
225	influenced by self-identifying as White (estimate = $4.679$ , $t = 2.153$ , $p = 0.037$ ). No other demographic
226	was significant.
227	
228	Discussion
229	The goal of this study was to investigate the role of demographics, pre-existing immunity, and
230	symptomatology following infection and vaccination to ascertain whether they independently or
231	collectively are associated with immunogenicity following mRNA vaccination for COVID-19 in individuals
232	previously infected with SARS-CoV-2. Our results demonstrate higher durability and robustness of
233	antibody titers despite a faster rate of antibody decay following vaccination, which supports previously
234	reported findings [31] for SARS-CoV-2 mRNA vaccines. Unsurprisingly, our results also demonstrate that
235	a larger temporal gap between an individual's LPT and/or date of vaccination predict decline of antibody
236	titers over time.

238 Following infection alone, we found that the number of symptoms reported and difficulty breathing 239 during the COVID-19 course were predictive of higher antibody titers. This result supports existing 240 evidence [32, 33] that individuals who report a more severe or symptomatic SARS-CoV-2 infection have 241 higher peak titers than asymptomatic individuals. Our data also support higher peak antibody titers 242 following vaccination with increasing age [32, 34]. The possible relationship between the antibody titer 243 post-vaccination and vaccine reactogenicity is largely unknown. Given that strength of the antibody 244 response was shown to correlate with disease severity in patients with COVID-19, we hypothesized that 245 more prominent post-vaccination adverse reactions might be associated with a stronger immune 246 response. After receiving dose 1 of either Pfizer or Moderna's COVID-19 vaccine, the local symptom of 247 injection site redness was found to be significantly predictive for higher antibody titers following full 248 vaccination and could be an indicator of the early and more prominent immune response. Interestingly, 249 after dose 2 we found that fever was significantly predictive for higher antibody titers following full 250 vaccination, though it should be noted that asymptomatic individuals mounted robust immune 251 responses as well.

252

253 Most critically, our analysis demonstrates that in previously infected individuals, SARS-CoV-2 mRNA 254 vaccines result in a more robust antibody response than that following infection alone. Indeed, in 255 individuals with "hybrid immunity", antibody titers peak following full vaccination at 4-fold higher than 256 those following naturally acquired immunity and appear to persist at detectable levels for >500 days 257 following vaccination. One explanation for this increased response could be the presence of pre-existing 258 memory T and B cell responses developed during natural infection. These cells might enhance a 259 secondary immune response following vaccination similar to that of a booster immunization. In addition 260 to bolstering the current CDC recommendations [35] that individuals previously infected with SARS-CoV-261 2 receive vaccination, our results provide additional, longitudinal support for this measure. In addition

262	to lowering the risk of re-infection [36, 37], vaccination clearly increases an individual's immune

- response [38, 39], which is vitally important as SARS-CoV-2 continues to produce variants capable of
- immune evasion, such as Delta (B.1.617.2) and Omicron (B.1.1.529) [40].

265

Current evidence supports a stronger reactogenic profile (both systemic and local) following the first 266 267 vaccine dose in previously infected individuals [41, 42], though it is worth noting that the median time 268 between COVID-19 to the first dose of vaccine in the studies cited above was either not reported or was 269 only 2.9 months. In our cohort, there is considerable variability between participants in days elapsed from LPT to time of vaccination  $(1^{st}$  dose median = 99 days; 95% CI = 72–159 days;  $2^{nd}$  dose median = 270 271 127 Days; 95% CI = 93-180 days). Given current knowledge regarding antibody decline, it is reasonable 272 to posit that a longer temporal gap between SARS-CoV-2 infection and vaccination may have resulted in a more reactogenic response to the 2<sup>nd</sup> dose of vaccine when compared to participants who had shorter 273 274 intervals between infection and vaccination as noted in the studies described above. 275 276 Previous work [43] examining the relationship between SARS-CoV-2 vaccine reactogenicity and

277 immunogenicity has been limited by assay type (i.e., semi-quantitative assays) and only deigned to 278 measure immunity immediately following vaccination. Another group [44] conducted a survey to assess 279 reactogenicity of COVID-19 vaccines and found that previous infection was associated with an increased 280 risk of reporting any side effect. They also found that mRNA vaccines seemed to produce milder, less 281 frequent systemic side effects but more local reactions in comparison to vector vaccines (i.e., Oxford 282 AstraZeneca AZD1222), which are consistent with our findings following the 1<sup>st</sup> dose. To our 283 knowledge, we are the first to examine predictors of reactogenicity and immunogenicity following SARS-284 CoV-2 vaccines in participants with prior COVID-19.

285

286	Intrinsic factors, such as age, gender, and ethnicity are thought to influence immunogenicity, but little is
287	known about the impact of ethnicity in particular [19]. Our study was conducted in Miami-Dade County,
288	an international, multi-cultural hub where the population is largely Hispanic and bilingual. Notably, our
289	analysis demonstrated a significant relationship between ethnicity (Hispanic) and higher antibody titers
290	over time at nearly every time point of interest, including infection where the analysis approached
291	significance ( $p = 0.0624$ ). Other groups have demonstrated higher rates of Hispanic SARS-CoV-2
292	seroconversion when compared to other ethnicities [45, 46] and have found that Hispanic ethnicity is
293	linked to higher rates of seroprotection and seroconversion following H1N1 monovalent vaccination [47,
294	48], but additional future studies with a large number of participants are needed to support a
295	generalizable trend for antibody magnitude over time in this population.
296	
297	In addition, we found that influenza vaccination was associated with higher antibody titers in our model
298	examining symptoms following the 2 <sup>nd</sup> dose and antibody titers following full vaccination, though it was
299	not found to be significant following post-hoc testing. Although biological relevance for this finding is
300	unknown, our group has previously shown that specific A(H1N1) CD4 responses correlate with SARS-
301	CoV-2 specific CD4 T-cells, suggesting a protective effect of pre-existing influenza specific T-cells [7]. We
302	speculate that this finding provides evidence for healthy and "trained" immune systems within our
303	cohort, wherein epigenetic and metabolic reprogramming have augmented innate immune cells that
304	enhance adaptive immunity to increase SARS-CoV-2 specific responses [7, 49].
305	
306	Our study has several limitations. Sample sizes for each cohort examined were small due to variability in
307	vaccination timelines and participant scheduling. Some individuals were excluded due to a confounding
308	effect on our predictive modeling, which is controlled by the fixed effect of time. The natural infection
309	group was further limited by the study timeline, as the first SARS-CoV-2 vaccination became available

310 shortly after enrollment began and therefore limited the number of individuals we were able to follow 311 longitudinally. Additionally, our analysis only included quantitative antibody binding titers. Although 312 recent work has demonstrated that higher binding antibodies correlate to higher neutralizing antibodies 313 [13], expansive, multi-center longitudinal studies are needed. An ideal analysis would consist of a 314 multivariate analysis of reactogenicity, demographics, and quantitatively characterized antibody, B-cell 315 and T-cell responses, as immune protection seems to be contingent on all three tiers of the immune 316 response [50]. Further, some of the predictors used in our statistical analysis were found to be 317 significant in one test but not in post-hoc tests. Large, longitudinal studies are required to confirm a 318 significant group difference, but the predictors utilized herein should be included in future analyses. Our bivariate analysis of symptoms experienced following the 1<sup>st</sup> and 2<sup>nd</sup> doses failed to demonstrate 319 320 that individual symptoms can influence peak antibody titers following full vaccination. The same was 321 true for race and ethnicity, which were not found to be significantly predictive for peak titers over time, 322 though we contend that this is because these models failed to control for individual differences, or 323 intercepts, to account for between-subjects' variability. 324 325 In conclusion, this work supports vaccination in COVID-19+ individuals to assure the most robust 326 immune response possible. A combination of systemic and local symptoms is predictive of higher 327 antibody titers, which may correlate to a higher degree of protection. While more work is needed to 328 understand the role of antibodies against SARS-CoV-2 infection and breakthrough infection, particularly 329 in the age of boosters and variants capable of immune escape, repeating this type of analysis at the

population level will be critical in providing individual recommendations for future vaccine measures.

## 331 Funding

- 332 This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine
- 333 Innovation Centers (CIVIC) contract 75N93019C00051.
- 334

## 335 Acknowledgements

336 We express our sincerest gratitude to our intellectually curious and willing study participants for

donating their blood and time to this study. We also thank the core research team that have made this

- 338 study logistically possible, including Margaret Roach, Elizabeth Varghese, Celeste Sanchez, Ailet Reyes,
- and the entire team of phlebotomists at the University of Miami's Clinical Translational Research Site.
- 340

## 341 Conflicts of Interest

342 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 343 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503 and 344 63/024,436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional Application Number: 63/251,020) which list Florian Krammer as co-inventor. Patent applications were submitted by the Icahn School of 345 346 Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market serological tests for 347 SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Third Rock Ventures, Segirus and Avimex. The Krammer laboratory is also 348 349 collaborating with Pfizer on animal models of SARS-CoV-2.

- 350
- 351 All other authors declare that they have no known competing financial interests or personal

352 relationships that could have appeared to influence the work reported in this paper.

354	Works Cited			
355 356	1. Rodebaugh TL, Frumkin MR, Reiersen AM, et al. Acute Symptoms of Mild to Moderate COVID-19 Are			
357	Highly Heterogeneous Across Individuals and Over Time. Open Forum Infect Dis 2021; 8:ofab090.			
358	2. Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clin Microbiol			
359	Rev <b>2019</b> ; 32:e00084-18.			
360	3. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune			
361	protection from symptomatic SARS-CoV-2 infection. Nature Medicine <b>2021</b> ; 27:1205-11.			
362	4. Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease			
363	severity and survival. Cell 2021; 184:476-88.e11.			
364	5. da Silva Antunes R, Pallikkuth S, Williams E, et al. Differential T-Cell Reactivity to Endemic			
365	Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. The Journal of Infectious			
366	Diseases <b>2021</b> ; 224:70-80.			
367	6. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in			
368	unexposed humans. Science <b>2020</b> ; 370:89-94.			
369	7. Pallikkuth S, Williams E, Pahwa R, Hoffer M, Pahwa S. Association of Flu specific and SARS-CoV-2			
370	specific CD4 T cell responses in SARS-CoV-2 infected asymptomatic heath care workers. Vaccine <b>2021</b> .			
371	8. Thevarajan I, Buising KL, Cowie BC. Clinical presentation and management of COVID-19. Med J Aust			
372	<b>2020</b> ; 213:134-9.			
373	9. FDA. Coronavirus Disease 2019 (COVID-19) EUA Informatin. Available at:			
374	https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-			
375	framework/emergency-use-authorization#vaccines. Accessed 13 January 2022 2022.			
376	10. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion			
377	in humans. Nature Medicine <b>2020</b> ; 26:1033-6.			

- 11. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed
- 379 Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol 2020;
- 380 57:e100.
- 12. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic
- 382 SARS-CoV-2 infection. Nature Medicine **2021**; 27:2032-40.
- 13. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273
- 384 COVID-19 vaccine efficacy clinical trial. Science; 0:eab3435.
- 14. Crawford KHD, Dingens AS, Eguia R, et al. Dynamics of Neutralizing Antibody Titers in the Months
- After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis 2021; 223:197-205.
- 15. Nagura-Ikeda M, Imai K, Kubota K, et al. Clinical characteristics and antibody response to SARS-CoV-2
- 388 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan. J Med
- 389 Microbiol **2021**; 70:001291.
- 390 16. Callegaro A, Borleri D, Farina C, et al. Antibody response to SARS-CoV-2 vaccination is extremely
- vivacious in subjects with previous SARS-CoV-2 infection. J Med Virol 2021; 93:4612-5.
- 392 17. Lozano-Ojalvo D, Camara C, Lopez-Granados E, et al. Differential effects of the second SARS-CoV-2
- 393 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep 2021;
- 394 36:109570.
- 18. Mungmunpuntipantip R, Wiwanitkit V. Antibody response to SARS-CoV-2 vaccination, previous
- 396 SARS-CoV-2 infection, and change to single-dose vaccination. J Med Virol **2021**; 93:6474.
- 19. Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how's and what's of
- 398 vaccine reactogenicity. npj Vaccines **2019**; 4:39.
- 20. Salazar E, Christensen PA, Graviss EA, et al. Significantly Decreased Mortality in a Large Cohort of
- 400 Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing

- 401 High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. Am J
- 402 Pathol **2021**; 191:90-107.
- 403 21. Tsang JS, Dobaño C, VanDamme P, et al. Improving Vaccine-Induced Immunity: Can Baseline Predict
- 404 Outcome? Trends in Immunology **2020**; 41:457-65.
- 405 22. HANC. Cross-Network PBMC Processing Standard Operating Procedure, **2018**:1-45.
- 406 23. CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized
- 407 in the United States. **2022**.
- 408 24. R Development Core Team. R: A language and environment for statistical computing. R Foundation
- 409 for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing **2021**.
- 410 25. Wood SN. Stable and efficient multiple smoothing parameter estimation for generalized additive
- 411 models. Journal of the American Statistical Association **2004**; 99:673-86.
- 412 26. Kuhn M. caret: Classification and Regression Training. R Package. 6.0-89 ed, 2021.
- 413 27. Friedman JH, Trevor; Tibshirani, Robert Regularization Paths for Generalized Linear Models via
- 414 Coordinate Descent. Journal of Statistical Software **2010**; 33(1):1-22.
- 415 28. Pinheiro J BD, DebRoy S, Sarkar D, R Core Team. \_nlme: Linear and Nonlear Mixed Effects Models. R
- 416 package version 31-152, **2021**.
- 417 29. Torsten H BF, Westfall P. Simultaneous Inference in General Parametric Models. Biometric Journal
- 418 **2008**; 50:346-63.
- 419 30. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, **2016**.
- 420 31. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine
- 421 over 6 Months. New England Journal of Medicine **2021**; 385:e84.
- 422 32. Röltgen K, Powell AE, Wirz OF, et al. Defining the features and duration of antibody responses to
- 423 SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol **2020**; 5.

- 424 33. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in
- 425 Iceland. New England Journal of Medicine **2020**; 383:1724-34.
- 426 34. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months
- 427 after infection. Science **2021**; 371.
- 428 35. CDC. Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity. **2021**.
- 429 36. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with
- 430 antibody-negative health-care workers in England: a large, multicentre, prospective cohort study
- 431 (SIREN). Lancet **2021**; 397:1459-69.
- 432 37. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who Previously Tested
- 433 Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. Clin Infect Dis 2021; 73:1882-6.
- 434 38. Regev-Yochay G, Amit S, Bergwerk M, et al. Decreased infectivity following BNT162b2 vaccination: A
- 435 prospective cohort study in Israel. The Lancet Regional Health Europe **2021**; 7.
- 436 39. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the
- 437 B.1.1.7 and B.1.351 Variants. N Engl J Med **2021**; 385:187-9.
- 438 40. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern.
- 439 Accessed 29 November 2021 2021.
- 440 41. d'Arminio Monforte A, Tavelli A, Perrone PM, et al. Association between previous infection with
- 441 SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078
- 442 health care workers. EClinicalMedicine **2021**; 36.
- 443 42. Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in
- 444 users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet
- 445 Infectious Diseases **2021**; 21:939-49.
- 446 43. Hwang YH, Song KH, Choi Y, et al. Can reactogenicity predict immunogenicity after COVID-19
- 447 vaccination? Korean J Intern Med **2021**; 36:1486-91.

- 448 44. Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-Reported Real-World Safety and
- 449 Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel) 2021; 11.
- 450 45. Kennedy JL, Forrest JC, Young SG, et al. Temporal Variations in Seroprevalence of SARS-CoV-2
- 451 Infections by Race and Ethnicity in Arkansas. medRxiv **2021**:2021.07.15.21260213.
- 452 46. Rogawski McQuade ET, Guertin KA, Becker L, et al. Assessment of Seroprevalence of SARS-CoV-2 and
- 453 Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia. JAMA Network Open
- 454 **2021**; 4:e2035234-e.
- 455 47. Pass RF, Nachman S, Flynn PM, et al. Immunogenicity of Licensed Influenza A (H1N1) 2009
- 456 Monovalent Vaccines in HIV-Infected Children and Youth. Journal of the Pediatric Infectious Diseases
- 457 Society **2013**; 2:352-60.
- 458 48. Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age.
- 459 New England Journal of Medicine **2010**; 362:370-2.
- 460 49. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health
- 461 and disease. Nature Reviews Immunology **2020**; 20:375-88.
- 462 50. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity to SARS-
- 463 CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell **2020**; 183:996-1012.e19.



Figure 1: Antibody response following natural infection and vaccination

Each black point represents a sample from a participant, grey lines connect points from the same participant, and the grey shaded area represents the maximum number of days between doses relative to date of full vaccination (14 days after second dose, regardless of vaccine manufacturer). A) Days since full vaccination vs. log titers over time. t=0 on the x-axis represents the day when COVID+ participants became fully vaccinated (2 weeks after second vaccination). Bi-phasic, generalized additive model (GAM) is visualized by a blue line. B) In unvaccinated COVID+ participants, log<sub>2</sub> antibody titers decay at a rate of -0.010 per day after last positive COVID-19 test result. Fitted linear model is visualized by a red line. Note that three points were excluded from the above figure due to the temporal scale used to graphically depict the data but are included in the analyses herein. C) In vaccinated COVID+ participants, log<sub>2</sub>

antibody titers decay at a rate of -0.015 per day after full vaccination. Fitted linear model is visualized by

a green line.

Figure 1: Symptoms experienced during infection significantly influences peak titer responses following full vaccination.



Number of symptoms during COVID-19 infection were positively correlated with peak  $\log_2$  COVID-19 antibody titers following full vaccination (Pearson's r = 0.296; p = .041)

Table 1: Characteristics of the Study Population Following Natural Infection, 1st Dose of Vaccine, and

# 2nd Dose of Vaccine

	Post Infection	Post Dose 1	Post Dose 2
n	33	49	48
Gender, M/F	14/19	17/32	16/32
Race	White [25 (76%)]	White [39 (80%)]	White [(39 (81%)]
	Black/African American	Black/African	Black/African American
	[2 (6%)]	American [2 (4%)]	[2 (4%)]
	Asian [1 (3%)]	Asian [2 (4%)]	Asian [2 (4%)]
	Other [5 (15%)]	Other [6 (12%)]	Other [5 (110%)]
Ethnicity, Hispanic/Not	14/19 (42%/58%)	22/27 (45%/55%)	21/27 (44%/56%)
Hispanic			
Median age [Range]	39 [20-76]	39 [20-78]	39 [20-78]
Vaccine manufacturer,	-	31/18 (63%/37%)	30/18 (62.5%/37.5%)
Pfizer/Moderna			
Median days since COVID	101	-	-
diagnosis by PCR to entry	74.87		
SD	8 - 292		
Range			
Median days since COVID	-	99	127
diagnosis by PCR to			
vaccination		72 – 159	102-180
95% Cl			

<sup>a</sup> Each count is the number of individuals who self-reported each symptom at the timepoint listed in

each column. Percentages are based on the total n for each column.

<sup>b</sup> All samples collected following natural infection were included for analysis.

Table 1: Symptoms Experienced by the Study Cohort Following Natural Infection, 1st Dose of Vaccine,

# and 2nd Dose of Vaccine

	Post Infection	Post Dose 1	Post Dose 2
Symptoms Reported During			
SARS-CoV-2 Infection <sup>a</sup>			
Asymptomatic	10 (20%)	-	-
Anosmia	27 (55%)	-	-
Congestion/rhinorrhea	26 (53%)	-	-
Cough	23 (47%)	-	-
Difficulty breathing	12 (24%)	-	-
Dysgeusia	26 (53%)	-	-
Fatigue	31 (63%)	-	-
Fever	18 (37%)	-	-
Myalgias	28 (57%)	-	-
Nausea or vomiting	5 (10%)	-	-
Sore Throat	15 (31%)	-	-
Upset Stomach	14 (29%)	-	-
Local Symptoms Reported			
Following Vaccination <sup>a</sup>			
Injection site pain	-	25 (51%)	26 (53%)
Injection site redness	-	2 (4%)	4 (8%)
Injection site swelling	-	4 (8%)	5 (10%)
Systemic Symptoms Reported			

Following Vaccination <sup>a</sup>			
Asymptomatic	-	22 (45%)	20 (41%)
Chills	-	9 (18%)	11 (22%)
Fatigue	-	14 (29%)	19 (39%)
Fever	_	10 (20%)	10 (20%)
Headache	_	14 (29%)	12 (24%)
Myalgias/Muscle	-	12 (24%)	14 (29%)
Aches			

<sup>a</sup> All symptoms reported during SARS-CoV-2 Infection, as well as local and systemic symptoms following

vaccination were included in LASSO modeling as shown in Supplementary Table 1.

# Table 1: Symptoms and demographic factors influence antibody responses following natural infection

and full vaccination

Category	Predictor	Coefficient <sup>®</sup>	F-value <sup>ª</sup>	p-value <sup>ª</sup>	Pr(> z ) <sup>b</sup>
Demographics, sy	mptoms reported during infection	on and titers fol	lowing natural in	fection	
Days elapsed	Days since positive test	-0.01	9.991	0.004*	
Symptoms	Difficulty breathing	0.58	5.684	0.024*	0.020*
reported during					
infection					
	Subjective symptom severity	0.00	2.524	0.123	
Demographics, sy	mptoms reported during infection	on and titers fol	lowing full vaccir	nation	
Days elapsed	Days since full vaccination	-0.01	258.176	<0.0001*	
Symptoms	Anosmia during infection	0.31	2.910	0.096	
reported during					
infection					
Demographics	Age	0.01	6.000	0.019*	
	Ethnicity (Hispanic)	0.20	5.265	0.027*	0.062
	Flu vaccinated	-0.37	3.612	0.064	
	Gender (Male)	-0.09	2.402	0.129	
	Vaccine manufacturer (Pfizer)	-0.16	0.306	0.583	
Demographics, sy	mptoms reported following Dos	e 1, and titers fo	ollowing full vacc	ination	
Days elapsed	Days since full vaccination	-0.01	262.855	<0.0001*	
Symptoms	Chills after 1 <sup>st</sup> dose	0.34	4.915	0.032*	0.085

reported after 1 <sup>st</sup>	<i>ed after 1<sup>st</sup></i> Injection site redness after 1 <sup>st</sup>		4.330	0.044*	0.038*
vaccine dose	dose				
Demographics	Age	0.01	6.960	0.012*	
	Ethnicity (Hispanic)	0.28	4.583	0.038*	0.017*
	Flu vaccinated	-0.15	1.771	0.191	
	Gender (Male)	-0.08	2.288	0.138	
Demographics, sy	mptoms reported following Dos	e 2, and titers f	ollowing full vacci	ination	
Days elapsed	Days since full vaccination	-0.01	259.745	<0.0001*	
Symptoms	Fever	0.61	11.154	0.002*	0.003*
reported after	Injection site swelling after	0.31	1.579	0.216	
2 <sup>nd</sup> dose	2 <sup>nd</sup> dose				
	Subjective symptom severity	-0.03	3.064	0.088	
Demographics	Age	0.01	7.652	0.009*	
	Ethnicity (Hispanic)	0.32	6.683	0.013*	0.006*
	Flu vaccinated	-0.29	4.405	0.042*	0.166
	Gender (Male)	-0.05	3.452	0.071	

Four LASSO models and linear mixed-effects (LME) p-values were generated to assess the predictive

value of categorical and discrete variables while controlling for between-subjects' differences.

Significant categorical LASSO-generated variables underwent additional post-hoc Tukey to test for directionality and to correct for multiple comparisons. A p-value <0.05 was considered statistically

significant.

<sup>a</sup> LME for predictors of main effects

<sup>b</sup> Post-hoc Tukey test for directionality of categorical variables due to significant main effects